Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study

BACKGROUND: Although endocrine therapy (ET) is the preferred option for hormone receptor-positive HER2-negative metastatic breast cancer (HR+/HER2– MBC), chemotherapy (CT) is still commonly used. The objective of this real-world study was to present the actual choice of first-line treatment for pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yang, Zhang, Shaohua, Yan, Min, Yin, Yongmei, Song, Yuhua, Jiang, Zefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184482/
https://www.ncbi.nlm.nih.gov/pubmed/34164465
http://dx.doi.org/10.21037/atm-20-8252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184482/
https://www.ncbi.nlm.nih.gov/pubmed/34164465
http://dx.doi.org/10.21037/atm-20-8252

Ejemplares similares